Merck is backing away from its patent cliff with a strong lineup of new products including Bridion (anesthesia), Saphris (schizophrenia), Simponi (immunology diseases), and Dulera (asthma).
Restructuring efforts should reduce costs and improve margins over the long term, helping to offset the patent expirations of high-margin products.
The acquisition of Schering enables Merck to potentially achieve more than $4 billion in annual cost-saving synergies by 2015. Read more
Merck is facing the loss of its largest sales contributor as the mid-2012 patent on Singulair expired.
Poor trial results from a key Schering pipeline product called TRA cast a cloud of increased uncertainty over the other pipeline products acquired in the Schering acquisition.
Poor results from the Enhance study combined with increased generic statin competition could reduce the market potential for Vytorin and Zetia. Read more
At the beginning of 2011, Ken Frazier took over the helm of Merck as CEO from Dick Clark and was also appointed as a chairman of the board in late 2011. With Clark nearing the age of retirement, we view the new leadership as a continuation of Merck's Read more
Merck makes pharmaceutical products to treat conditions in a number of therapeutic areas, including cardiovascular disease, asthma, infections, and osteoporosis. The company Read more
ACA 'Fix' Won't Cause Breakdown for Insurers Watch more